Saved in:
Bibliographic Details
Main Author: Etievant, Lola
Format: Preprint
Published: 2026
Subjects:
Online Access:https://arxiv.org/abs/2605.11768
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866914557668098048
author Etievant, Lola
author_facet Etievant, Lola
contents Studies of HPV vaccine efficacy usually record infections with vaccine targeted and nontargeted strains. Contrary to blinded randomized controlled trials, confounding bias can be a threat and risk compensation may occur in observational studies. Etievant et al. (Biometrics, 2023) proposed to use cervical infections with nontargeted HPV strains to reduce or remove confounding bias of estimates of vaccine efficacy on targeted strains. However, they assumed that vaccinated women could not change their behavior after vaccination. We consider a more plausible setting where unmeasured sexual behavior acts as both a confounder and a mediator, and investigate if the quantity estimated in practice with their method has a clear causal meaning. We demonstrate that using nontargeted HPV infections can remove both confounding bias and the portion of the vaccine effect on the targeted HPV strains that is mediated through the change of behavior. In that case, the estimated quantity has a clear causal interpretation as it represents the direct immunological effect of the vaccine. However, it could be considered misleading from a public health perspective, as in the presence of risk compensation it would suggest higher protection than what women effectively experience. An unblinded randomized controlled trial would allow estimation of the total causal effect of the vaccine, and infections with nontargeted HPV strains could then be used to isolate the indirect behavioral effect of the vaccine.
format Preprint
id arxiv_https___arxiv_org_abs_2605_11768
institution arXiv
publishDate 2026
record_format arxiv
spellingShingle Using NonTargeted HPV Infections in Studies with Risk Compensation
Etievant, Lola
Methodology
Studies of HPV vaccine efficacy usually record infections with vaccine targeted and nontargeted strains. Contrary to blinded randomized controlled trials, confounding bias can be a threat and risk compensation may occur in observational studies. Etievant et al. (Biometrics, 2023) proposed to use cervical infections with nontargeted HPV strains to reduce or remove confounding bias of estimates of vaccine efficacy on targeted strains. However, they assumed that vaccinated women could not change their behavior after vaccination. We consider a more plausible setting where unmeasured sexual behavior acts as both a confounder and a mediator, and investigate if the quantity estimated in practice with their method has a clear causal meaning. We demonstrate that using nontargeted HPV infections can remove both confounding bias and the portion of the vaccine effect on the targeted HPV strains that is mediated through the change of behavior. In that case, the estimated quantity has a clear causal interpretation as it represents the direct immunological effect of the vaccine. However, it could be considered misleading from a public health perspective, as in the presence of risk compensation it would suggest higher protection than what women effectively experience. An unblinded randomized controlled trial would allow estimation of the total causal effect of the vaccine, and infections with nontargeted HPV strains could then be used to isolate the indirect behavioral effect of the vaccine.
title Using NonTargeted HPV Infections in Studies with Risk Compensation
topic Methodology
url https://arxiv.org/abs/2605.11768